CAR-T In Vitro Efficacy Services with OncoSolid™ Ovarian Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Ovarian Cancer Organoid Model

Ovarian cancer is a female reproductive system-related tumor and brings crisis to female health and life. Immunotherapies, especially targeted cell therapy, are urgently needed to enhance the survival rate of patients. Organoid is a prevailing preclinical model for cancer research, drug screening, tumor response investigation, and personalized medicine. They stably recapitulate the cellular and molecular features of neoplasm in tumors but are also convenient to manipulate and analyze. Organoids have many advantages and have become a valuable tool for assessing CAR-T cell-mediated killing in vitro.

Fig.1 Organoids of epithelial ovarian cancer (EOC) is an attractive preclinical in vitro model. (Yang, et al., 2021)

Ovarian Cancer Organoids-Based CAR-T Service at Creative Biolabs

Organoid Characterization

We provide a complete evaluation of the formed 3D “mini-organ” before the application for drug screening and efficacy tests. Morphological and histological characterization Genomic characterization Histology heterogeneity evaluation

Ovarian Cancer Organoid Subtypes

Multiple subtypes of ovarian cancer organoids consist of a high throughput platform for CAR-T efficacy tests.

Group	Subtypes	Characters
Borderline Tumors (BT)	Serous BT Mucinous BT	Non-carcinoma.
Type I	Low-grade serous (LGS) Mucinous (MC) Endometrioid (END) Clear cell (CCC) carcinomas	Carcinomas, and having mutations in BRAF, PTEN, and CTNNB1.
Type II tumors	High-grade serous (HGS) tumors	Carcinomas, and having mutation in TP53, BRCA1, and BRCA2.

Optimized Culture System

The Optimal Medium for Efficient Organoid Establishment
Base ovarian organoids medium plus with tumor-related proteins and growth factors; The optimal medium for each organoid line; Support long-time culture and passage; Support cryopreserved and efficiently recovered.

Highlights

Our Ovarian Cancer-related CAR-T Products

We provide the following target-specific CAR-T cells and corresponding construction products for in vitro anti-tumor efficacy evaluation. The products include CAR vector products, CAR cells, CAR-viral particle products, etc.

Target Antigen	Target Description	CAR-T Products
OR2H1	OR2H1 belongs to the olfactory receptors family. The expression level of OR2H1 is increased in tumors but has limited expression in normal tissue.	Anti-OR2H1 CAR-T
Mesothelin	Mesothelin is a surface antigen protein expressed in 70 percent of ovarian cancers and is a target for cancer therapies.	Anti-Mesothelin CAR-T
MUC1	MUC1 is overexpressed in epithelial ovarian cancer (EOC) and is associated with tumor metastasis and progression.	Anti-MUC1 CAR-T
FRα	FRα, a receptor to folate, is a carcinomas-related antigen with an elevated expression on aggressive ovarian carcinomas cells.	Anti-FRα CAR-T
NKG2D	NKG2D is a common tumor-associated protein and is present in over 80% of primary ovarian cancer.	Anti-NKG2D CAR-T
CD47	CD47 protein has a high expression level in ovarian cancer and plays a crucial role in inhibiting macrophage phagocytosis and cancer progression.	Anti-CD47 CAR-T
B7-H3	B7-H3 protein expression in ovarian cancer is involved in tumor growth and developing resistance against chemotherapy. B7-H3 has become a target for ovarian cancer treatment.	Anti-B7-H3 CAR-T
CD70	CD70 is a new target for multiple solid tumor treatment and is overexpressed in ovarian cancer, which plays a role in chemotherapy resistance and poor survival.	Anti-CD70 CAR-T

Creative Biolabs is experienced in organoid establishment and CAR-T construction. If you are interested in any aspect of our services, please contact us for more detailed information.

References

Kopper, O.; et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature medicine. 2019, 25(5): 838-849.
de Witte, C. J.; et al. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. Cell reports. 2020, 31(11): 107762.
Yang, J.; et al. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. Frontiers in cell and developmental biology. 2021, 9: 701429.